Pfizer's Disappointing Prognosis

Investors hope 2006 will be a year of healing for the drugmaker. But the latest earnings are a hard pill to swallow

Pfizer (PFE) investors were disappointed by the company's lackluster earnings outlook on Feb. 10. The stock fell more than 2%, to $25.65, as the company said earnings per share in 2006, excluding the costs associated with its ongoing restructuring program, would be about flat with 2005 at $2. That was slightly below what Wall Street had been expecting (see BW Online, 2/8/06, "Pfizer Feels Investors' Pain").

To continue reading this article you must be a Bloomberg Professional Service Subscriber.